pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Advanced Systemic Mastocytosis, Systemic Mastocytosis, GIST, Indolent Systemic Mastocytosis, Indolen
Cambridge, USA HQ
2011 Founded
741 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2011
- Employees
- 741
- Programs
- 8
- Drugs
- 9
- Patents
- 0
AZACITIDINE
Phase 2 · small molecule · Advanced Systemic Mastocytosis
AZACITIDINE for Advanced Systemic Mastocytosis is a Phase 2 program (small_molecule) at Blueprint Medicines (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).
Internal code BLU-263-2101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Blueprint Medicines (Netherlands) B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Systemic Mastocytosis
- Status
- active
- Trials
- 1